Affect Therapeutics Company Profile

Background

Founded in 2020, Affect Therapeutics is a digital health company dedicated to transforming addiction treatment through innovative, technology-driven solutions. The company's mission is to provide accessible, effective, and personalized treatment for substance use disorders (SUDs) via a smartphone application. By integrating evidence-based methodologies with digital convenience, Affect Therapeutics aims to address the escalating addiction crisis in the United States.

Key Strategic Focus

Affect Therapeutics specializes in delivering digital treatments for various substance use disorders, including alcohol, marijuana, cocaine, methamphetamine, and prescription stimulants like ADHD medications. The core of their strategy involves:

Contingency Management: Implementing financial incentives to reward healthy behaviors and encourage sustained sobriety.

Comprehensive Digital Therapy: Offering a suite of services such as individual and group therapy sessions, medical consultations, and case management, all accessible through their mobile application.

Data-Driven Personalization: Utilizing user data to tailor treatment plans, enhancing engagement and effectiveness.

This approach not only increases treatment accessibility but also aligns with contemporary healthcare trends emphasizing personalized and patient-centric care.

Financials and Funding

As of July 2023, Affect Therapeutics has raised a total of $23 million in funding. The most recent funding round, a $16 million Series A, was led by ARTIS Ventures, with participation from AlleyCorp, CityLight, LifeArc Ventures, Samsung Next, and What If Ventures. This capital infusion is earmarked for national expansion, program development, and technological enhancements to the Affect app.

Technological Platform and Innovation

Affect Therapeutics distinguishes itself through its proprietary digital platform, which integrates:

Gamification and Behavioral Engineering: Incorporating game-like elements to stimulate the brain's reward center, fostering engagement and promoting sustained behavioral change.

Telehealth Integration: Facilitating secure video conferencing for therapy sessions, medical consultations, and group meetings, ensuring comprehensive care delivery.

Data Analytics: Employing advanced analytics to monitor progress, personalize treatment plans, and predict potential relapse risks.

This innovative use of technology positions Affect Therapeutics at the forefront of digital addiction treatment.

Leadership Team

Kristin Muhlner, CEO: Brings extensive experience in building digital technology companies, with prior leadership roles at Framebridge, Sprinklr, newBrandAnalytics, and webMethods.

Dr. Jon Peeples, Chief Medical Officer: A board-certified psychiatrist with a background in nonprofit health systems, government health systems, and startups, previously serving as Chief of Psychiatry at the Mann-Grandstaff VA Medical Center.

Bryan Prout, Head of Clinical and Operations: Leads the member journey, leveraging significant experience in building customer-centric organizations.

Will Herling, Head of Partnerships: Combines expertise in value-based care and addiction advocacy to build transformative partnerships.

Russell Osborne, Chief Technology Officer: Brings a passion for technology and design, with over fifteen years of experience in software development across various industries.

Natalie Pitcher Clark, Head of Marketing: Leverages storytelling, customer empathy, and data to drive marketing initiatives, with prior experience at Stardog, Starry Internet, and Mapbox.

Competitor Profile

Market Insights and Dynamics

The digital health sector, particularly in addiction treatment, is experiencing significant growth. The increasing prevalence of substance use disorders, coupled with the demand for accessible and effective treatment options, has led to a surge in digital therapeutic solutions. The market is characterized by rapid technological advancements, regulatory developments, and evolving patient preferences.

Competitor Analysis

Key competitors in the digital addiction treatment space include:

Pear Therapeutics: Offers prescription digital therapeutics for substance use disorders, focusing on evidence-based interventions.

Quit Genius: Provides a digital clinic for multiple addictions, combining behavioral therapy with medication-assisted treatment.

Workit Health: Delivers virtual care for addiction recovery, offering therapy, medication, and community support through a mobile app.

These companies, like Affect Therapeutics, leverage technology to enhance treatment accessibility and efficacy, contributing to a competitive and rapidly evolving market landscape.

Strategic Collaborations and Partnerships

Affect Therapeutics has established partnerships with major health insurance providers, including UnitedHealthcare, Aetna, Humana, Molina, and Centene. These collaborations facilitate broader access to their digital treatment programs and underscore the company's commitment to integrating with existing healthcare infrastructures.

Operational Insights

Affect Therapeutics' strategic focus on digital delivery and contingency management differentiates it from traditional rehab models. By offering a fully digital, accessible, and personalized treatment program, the company addresses common barriers to addiction treatment, such as cost and accessibility. This approach not only enhances patient engagement but also positions Affect Therapeutics as a leader in the digital transformation of addiction care.

Strategic Opportunities and Future Directions

With outpatient treatment licenses in 20 states and plans to serve a majority of the U.S. population by the end of 2023, Affect Therapeutics is poised for significant growth. The recent Series A funding will support national expansion, program development, and technological innovation. By continuing to leverage data-driven insights and strategic partnerships, Affect Therapeutics aims to redefine addiction treatment and improve outcomes for individuals nationwide.